Have you ever wondered what happens when the biggest hedge funds and mutual funds quietly agree on the same handful of stocks? I have watched this particular list for years, and the results keep surprising me. A rolling portfolio built from those overlapping favorites is already up 29 percent this year. That is a solid 13 percentage points ahead of the equal-weighted S&P 500. The latest quarterly snapshot just landed, and three fresh names joined the circle.
Why Shared Favorites Keep Beating the Broader Market
Every quarter the same exercise repeats. Analysts dig through thousands of 13F filings and isolate the names that sit at the exact center of two different worlds: aggressive hedge-fund positions and large-cap mutual-fund overweights. Those names become the shared favorites. The group is never static. It shifts with the filings, and that constant refresh has produced an annualized return of 17 percent since 2013. The ride is bumpier than the average index, with a standard deviation around 22 percent, yet the long-term edge has held.
I find the consistency almost unsettling. In my experience, when both sophisticated short-term traders and patient long-only managers crowd into the same equities, something fundamental is usually shifting beneath the surface. This quarter the shift is unmistakable: financials are back in favor in a way we have not seen for a long time.
The Six Names Sitting in the Overlap Right Now
Six companies currently occupy that narrow Venn-diagram center. Three of them are familiar faces, three are brand-new arrivals. The complete list reads: Boeing, Capital One Financial, Mastercard, SpaceX, Thermo Fisher Scientific, and Visa. Capital One, SpaceX, and Thermo Fisher Scientific are the fresh additions for the third quarter.
What stands out immediately is the heavy presence of payment networks and a major consumer-finance name. Visa and Mastercard have been perennial favorites for years, yet the arrival of Capital One suggests managers are broadening their financial exposure rather than simply doubling down on the same two processors. SpaceX brings a private-market flavor that is rare in these public-filing screens, while Thermo Fisher adds a defensive growth element from the life-sciences tools sector.
The Quiet Rotation Into Financials
Perhaps the most interesting aspect of the latest data is the sector tilt. Hedge funds raised their net exposure to financials by more than three percentage points during the second quarter. That move pushed their overweight in the sector to the highest level recorded since before the Global Financial Crisis. Mutual funds followed the same path and now sit at their largest overweight in financials since at least 2012.
Both groups are overweight financials at the same time for only the third occasion in the historical record. That kind of rare alignment rarely happens by accident. Managers appear to be positioning for a backdrop of higher-for-longer rates, improving credit conditions, or simply a relative-value opportunity after years of under-ownership.
Hedge funds increased their net tilt toward Financials by over three percentage points during Q2 to the largest position in the sector since prior to the Global Financial Crisis. Mutual funds also increased their tilt to Financials last quarter and now carry their largest overweight since at least 2012.
I have seen sector rotations come and go, but the simultaneous move by two very different investor bases feels more deliberate than usual. Capital One’s appearance alongside the two payment giants reinforces the theme. The stock gives managers direct exposure to consumer lending and deposit gathering rather than pure transaction processing.
How the Rolling Portfolio Has Performed Over Time
The track record is hard to ignore. Since 2013 the shared-favorites basket has delivered that 17 percent annualized return. Yes, volatility runs higher than the broader market, yet the excess return has more than compensated patient holders. Year-to-date the same approach is already ahead by 29 percent versus the equal-weighted S&P 500’s lower figure.
Valuation is the usual trade-off. The median shared favorite currently trades at a price-to-earnings multiple of 25 times, compared with roughly 19 times for a typical S&P 500 name. Investors are paying a premium for the quality and growth characteristics that both hedge funds and mutual funds seem to prize. Whether that premium is justified depends on the earnings delivery that follows, but history suggests the group has often grown into its multiples.
What the Scale of the Data Really Means
The latest screen covers an enormous slice of institutional capital. Roughly 10 trillion dollars of equity positions were analyzed at the start of the third quarter. That total splits into 991 hedge funds holding 5.4 trillion dollars of gross equity exposure and 504 large-cap active mutual funds managing 4.6 trillion dollars. When a name appears in both universes, it has survived two very different selection processes.
Hedge funds tend to move faster and lean into momentum or catalyst-driven ideas. Mutual funds usually favor durable competitive advantages and multi-year compounding stories. The overlap therefore represents a consensus that is neither purely short-term nor purely long-term. In my view that hybrid quality is exactly why the basket has held up across different market regimes.
Looking Closer at the New Additions
Capital One’s inclusion feels like the purest expression of the financials rotation. After years of relative neglect, the company offers a combination of scale in credit cards and a growing national bank franchise. Managers appear willing to accept the cyclical nature of consumer credit in exchange for the potential upside if credit costs remain contained.
SpaceX is the more unconventional newcomer. Its presence in public 13F data is limited, yet the fact that both hedge funds and mutual funds found ways to express exposure speaks to the intensity of interest in commercial space and satellite connectivity. The valuation is private-market driven, so public investors must accept less transparency than they would with a traditional listed name.
Thermo Fisher Scientific rounds out the new trio. The company sits at the intersection of biotech tools, diagnostics, and laboratory equipment. Demand from pharmaceutical research and clinical testing has remained resilient even when broader industrial spending slowed. Its addition gives the shared-favorites list a defensive growth ballast that offsets some of the cyclicality in the financial names.
Boeing, Mastercard, and Visa Remain Core Holdings
The three holdovers each bring their own story. Boeing continues to work through production challenges and regulatory scrutiny, yet the long-term order book and the eventual recovery in commercial aircraft demand keep institutional interest alive. Mastercard and Visa need little introduction. Their global payment networks still expand with digital commerce, and the secular shift away from cash remains a multi-year tailwind.
I have always been struck by how these two payment companies manage to stay relevant across wildly different economic environments. Whether rates are rising or falling, consumer spending patterns change, yet the volume of transactions processed continues to climb. That resilience explains their repeated appearance in the shared-favorites screen.
Volatility Comes With the Territory
None of this outperformance arrives free of risk. The 22 percent standard deviation is real. There have been quarters when the basket lagged badly, usually when crowded growth names corrected sharply. Investors who treat the list as a rigid buy-and-hold portfolio without position sizing or risk controls can experience uncomfortable drawdowns.
Still, the long-term arithmetic has favored those willing to stay the course. The excess return over the equal-weighted market has more than offset the extra volatility for anyone with a multi-year horizon. That is the part that keeps drawing me back to the data every quarter.
What the Premium Valuation Tells Us
Paying 25 times earnings instead of 19 times is not a trivial difference. It implies that the market, and by extension these large institutional holders, expects superior earnings growth or higher returns on capital. History shows the shared favorites have often delivered on that expectation, but there is no guarantee the pattern continues.
One practical way to think about the premium is relative to the alternatives. If the broader market is priced for modest growth and the shared favorites are priced for stronger growth, the key question becomes whether the growth differential materializes. So far the answer has been yes more often than no.
How Managers Appear to Be Thinking About Risk
The simultaneous overweight in financials by both hedge funds and mutual funds suggests a collective judgment that the sector’s risk-reward has improved. Credit metrics have stabilized in many consumer and commercial portfolios. Capital ratios at large banks remain elevated. Net interest margins, while past their peak, are still healthy by historical standards.
At the same time, the inclusion of Thermo Fisher and the continued presence of the payment networks provide ballast. The overall basket is not a pure cyclical bet. It mixes rate-sensitive financial exposure with secular growth stories and a defensive life-sciences name. That blend may help explain why the volatility, while elevated, has not been extreme enough to erase the excess returns.
The Role of 13F Timing and Data Lag
One practical limitation is worth keeping in mind. 13F filings arrive with a lag. By the time the public sees the second-quarter holdings, managers may already have adjusted positions in the third quarter. The shared-favorites list is therefore a lagging indicator of institutional consensus rather than a real-time signal.
Even with that lag, the performance of the rolling portfolio has remained robust. The edge does not depend on perfect timing of every entry and exit. It seems to stem more from the quality of the underlying businesses that repeatedly attract both types of capital.
Putting the Numbers in Perspective
A 29 percent year-to-date gain is impressive on its own. Outperforming the equal-weighted S&P 500 by 13 percentage points raises the bar further. Equal-weighted indexes already tilt away from the largest mega-cap names, so beating that benchmark suggests the shared favorites are delivering something beyond simple large-cap momentum.
I keep returning to the annualized 17 percent figure since 2013. That stretch includes multiple rate cycles, a pandemic, inflation spikes, and sharp equity corrections. The fact that the approach has continued to compound at that rate through such varied conditions is the strongest argument in its favor.
Practical Takeaways for Individual Investors
Most individual investors cannot replicate the exact basket in real time, especially when private-market exposure such as SpaceX is involved. What they can do is study the characteristics that keep appearing. High-quality franchises with durable competitive advantages, exposure to secular growth trends, and occasional cyclical recovery stories tend to dominate the list.
Diversification across those themes, rather than concentration in any single name, has historically been the more reliable path. The elevated volatility of the full basket also argues for position sizing that leaves room for inevitable pullbacks.
Where the Consensus Might Head Next
The current financials overweight is unusual enough that it will be watched closely in the coming quarters. If credit conditions deteriorate or rate cuts arrive faster than expected, managers may reverse course just as quickly as they entered. Conversely, if the economic soft landing continues, the tilt could persist or even deepen.
SpaceX’s presence raises another question. As more private companies stay private longer, institutional demand for creative ways to gain exposure will only grow. Future shared-favorites lists may contain a higher proportion of such hybrid public-private names.
A Final Thought on Consensus Investing
There is a natural skepticism toward any list of “favorite” stocks. Crowded trades can unwind painfully. Yet the shared-favorites approach has managed to turn institutional consensus into a source of excess return rather than a source of excess risk over more than a decade. That outcome is rarer than it should be.
The latest quarter simply continues the pattern. Three new names, a pronounced financials rotation, and another stretch of outperformance. Whether the edge persists will depend on earnings delivery and macroeconomic conditions that no one can forecast with certainty. For now the data still favors the names that sit at the center of both hedge-fund and mutual-fund attention.
I will be watching the next round of filings as closely as the last. The moment the overlap changes again, the rolling portfolio will adjust, and the performance clock will keep running. That quiet, methodical process has produced results worth paying attention to, even for investors who never intend to own every name on the list.
The numbers are clear enough. A 29 percent year-to-date advance, a long-term annualized return of 17 percent, and a rare simultaneous overweight in financials by two distinct investor groups. The six stocks currently in the overlap—Boeing, Capital One Financial, Mastercard, SpaceX, Thermo Fisher Scientific, and Visa—represent the latest expression of that institutional consensus. Capital One, SpaceX, and Thermo Fisher are the newest members, each bringing a different flavor of growth and cyclical recovery. The valuation premium remains elevated, the volatility is real, and the data lag is unavoidable. Yet the historical edge has proven durable enough to keep the approach relevant across multiple market cycles. For anyone tracking where large pools of sophisticated capital are concentrating, the shared-favorites screen continues to offer a useful, if imperfect, window.
